STOCKS TELEGRAPH

Tag: NASDAQ:MEDS

  • How Did The TRxADE (MEDS) Stock Rise 75%?

    TRxADE HEALTH, Inc. (NASDAQ: MEDS) experienced a significant boost in its stock value, surging by 75.98% during early trades on Wednesday, and reaching $11.65 per share at last check. This impressive rise came on the heels of the announcement of the release date for the company’s financial results.

    Looking ahead, TRxADE (MEDS) is set to unveil its financial results for the second quarter of 2023 after the market closes on August 14, 2023. The details of the financial performance will be made public through a press release, scheduled for dissemination after regular stock market trading hours on the same day as the conference call.

    In connection with the financial disclosure, a conference call hosted by MEDS’ management is scheduled for 6:00 p.m. Eastern time on August 14th, 2023. During this call, they will delve into the specifics of the second quarter’s financial performance and address any related inquiries.

    In recent news, TRxADE completed the acquisition of Superlatus, Inc., a U.S.-based holding company with a focus on food products and distribution capabilities.

    According to the amended and restated agreement and plan of merger, shareholders of Superlatus were granted 136,441 shares of MEDS common stock, representing 19.99% of the total issued and outstanding MEDS common stock at the time of the merger’s closing.

    Additionally, they received 306,855 shares of a new class of MEDS non-voting convertible preferred stock, with a conversion ratio of 100 to one, based on their pro rata percentage ownership.

    In a move to benefit its shareholders, on July 28, 2023, TRxADE issued non-transferable rights, offering one share of MEDS common stock at no cost, with seven (7) MEDS Rights allocated per share of TRxADE common stock held as of the same date.

    The eligibility for these rights extended to both existing MEDS shareholders and independent directors who were entitled to a certain amount of MEDS common stock as part of their 2023 annual compensation. Notably, this issuance was independent of whether the common stock had been issued or vested before July 28, 2023.

  • Why Is TRxADE (MEDS) Stock Skyrocketing Today, Spiking More Than 100%?

    At start of the trading today, shares of integrated drug procurement, delivery, and healthcare platform TRxADE HEALTH Inc. (MEDS) rose 112.26% to $9.36 at the time of this writing.

    TRxADE closed Wednesday’s session at $4.42, down 3.07 percent. MEDS shares traded at 0.28 million, a lower volume than the daily average of 4.26 million shares traded over the last 50 days. In the past year, MEDS share prices have fallen -26.33%, and this week they have declined -4.74%.

    MEDS stock has lost -15.65% over the past three months, while it has lost -18.30% over the past six months. As of June 30, MEDS had an outstanding share count of 8.09 million while its market value was $34.74 million. As its subsidiary launches a new program, the MEDS stock has gained traction.

    What was that program about?

    In the United States, TRxADE is a health services IT company dedicated to optimizing the prescription journey, drug procurement, and patient engagement through technology. TRxADE is a leading drug purchasing marketplace operated by MEDS, providing price transparency to 12,100+ members nationwide. A variety of telehealth services are offered by MEDS under the Bonum Health brand.

    TRxADE Bonum Health, TRxADE’s Digital Health business subsidiary, has signed a deal with Big Y Pharmacy and Wellness Centers in Massachusetts and Connecticut to distribute Telemedicine services.

    • Using Bonum Health’s mobile health services and prescriber program, staffed by more than 600 board-certified medical providers, Big Y pharmacies will be able to provide their patients with affordable telemedicine.
    • The partnership also offers Bonum Health prescription discount savings to Big Y patients.
    • and Connecticut see increasing numbers of uninsured and underinsured consumers, and consumers are clamoring for more affordable healthcare options.
    • Big Y entered into the collaboration to enhance its collaborative care network and to expand its digital healthcare offerings.
    • And Bonum Health could contribute to Big Y’s diversification of digital healthcare in-store and at the community level.
    • Through Bonum’s mobile application, Big Y pharmacies will be able to utilize a turnkey Telemedicine and prescription savings tool.
    • Furthermore, Big Y pharmacy leadership saw an opportunity to offer their patients deeply discounted, low-cost care through Bonum.
    • Additionally, Bonum Health will be expanding Big Y’s prescription discounts, using Bonum’s digital platform, for which Big Y has chosen Bonum Health.

    MEDS’ other development:

    MedCheks, another subsidiary of TRxADE, has recently launched the Health Passport app for iOS devices. With the MedCheks app, one can securely show medical records, such as vaccination records and test results, to gain entrance to a country, establishment, event or mode of transportation that requires proof of health. As COVID-19 subsides in certain markets, TRxADE HEALTH (MEDS) addresses the market need for cost-effective, advanced digital health applications to accelerate the reopening of the economy.

  • TRxADE (MEDS) Stock Is Down During Pre Market Trading, Can You Explain Why?

    TRxADE (MEDS) Stock Is Down During Pre Market Trading, Can You Explain Why?

    Today’s premarket session saw TRxADE Group Inc. (MEDS) shares decline -9.30% at $6.05. In the last trading session, TRxADE stock rose 63.48% to $6.67. MEDS stock appears to be heading for a retracement after yesterday’s gain.

    What led to a rise in the MEDS stock price?

    Health services IT company TRxADE optimizes drug procurement, prescription journeys, and patient engagement in the US by digitalizing the retail pharmacy experience. The Bonum Health brand offers telehealth services under the TRxADE brand, which is a drug procurement marketplace bringing price transparency to 12,100+ members across the country.

    The TRxADE subsidiary MedCheks has launched a mobile app, HealthPassport, that can be downloaded from the Apple App Store, announced MEDS yesterday.

    • The MedCheks app offers a QR code that can be used to show proof of health records securely once it is installed on an iOS device.
    • MEDS’ app will store health records, including vaccinations or test results, that will be needed to gain entry into a country, establishment, event or mode of transportation that requires verification protocols.
    • By providing advanced, cost-effective digital healthcare applications, TRxADE HEALTH is meeting the need to ease the reopening of the economy as COVID-19 subsides in some markets.

     How is MEDS planning to move forward?

    TRxADE (MEDS) app is a trusted platform that reestablishes daily operations in a secure manner so that organizations across all verticals can take advantage of the security, ease, and cost-effective measures that it provides. With its initial partners in the months ahead, MEDS is on track to launch successfully.